Stealth Therapeutics attained a long-awaited FDA approval for its mitochondrial-targeted therapy designed to treat Barth syndrome, marking a milestone for this rare genetic disorder. Barth syndrome lacks effective treatment options and is characterized by mitochondrial dysfunction affecting multiple organ systems. This approval introduces the first targeted therapy for patients, opening new therapeutic avenues for mitochondrial diseases and rare genetic conditions.